Chemomab Therapeutics Ltd
NASDAQ:CMMB
Income Statement
Earnings Waterfall
Chemomab Therapeutics Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-25.5m
USD
|
Operating Income
|
-25.5m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-24.2m
USD
|
Income Statement
Chemomab Therapeutics Ltd
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(3)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(3)
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(20)
|
(19)
|
(16)
|
(10)
|
(11)
|
(6)
|
(8)
|
(10)
|
(12)
|
(16)
|
(19)
|
(25)
|
(26)
|
(32)
|
(34)
|
(30)
|
(22)
|
|
Selling, General & Administrative |
(6)
|
(5)
|
(3)
|
(2)
|
(7)
|
(3)
|
(4)
|
(5)
|
(6)
|
(8)
|
(10)
|
(11)
|
(12)
|
(11)
|
(11)
|
(9)
|
(7)
|
|
Research & Development |
(13)
|
(11)
|
(9)
|
(4)
|
(4)
|
(3)
|
(4)
|
(4)
|
(6)
|
(8)
|
(10)
|
(13)
|
(14)
|
(21)
|
(23)
|
(21)
|
(15)
|
|
Other Operating Expenses |
0
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(20)
N/A
|
(19)
+2%
|
(16)
+18%
|
(10)
+38%
|
(11)
-13%
|
(6)
+43%
|
(8)
-26%
|
(10)
-21%
|
(12)
-29%
|
(16)
-29%
|
(19)
-22%
|
(25)
-28%
|
(29)
-15%
|
(32)
-13%
|
(34)
-6%
|
(30)
+12%
|
(25)
+16%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
1
|
1
|
1
|
|
Non-Reccuring Items |
(3)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(27)
N/A
|
(19)
+30%
|
(16)
+18%
|
(10)
+38%
|
(12)
-21%
|
(6)
+47%
|
(8)
-28%
|
(10)
-22%
|
(12)
-30%
|
(16)
-27%
|
(20)
-25%
|
(25)
-26%
|
(28)
-13%
|
(32)
-13%
|
(33)
-4%
|
(29)
+12%
|
(24)
+17%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
(0)
|
(0)
|
0
|
|
Income from Continuing Operations |
(27)
|
(19)
|
(16)
|
(10)
|
(12)
|
(6)
|
(8)
|
(10)
|
(12)
|
(16)
|
(19)
|
(24)
|
(28)
|
(31)
|
(33)
|
(29)
|
(24)
|
|
Net Income (Common) |
(27)
N/A
|
(19)
+30%
|
(16)
+18%
|
(10)
+38%
|
(12)
-21%
|
(6)
+47%
|
(8)
-28%
|
(10)
-22%
|
(12)
-30%
|
(16)
-27%
|
(19)
-22%
|
(24)
-26%
|
(28)
-13%
|
(31)
-13%
|
(33)
-6%
|
(29)
+12%
|
(24)
+17%
|
|
EPS (Diluted) |
-12.6
N/A
|
-2.33
+82%
|
-1.91
+18%
|
-0.67
+65%
|
-5.01
-648%
|
-0.62
+88%
|
-0.57
+8%
|
-0.67
-18%
|
-0.96
-43%
|
-1.1
-15%
|
-1.35
-23%
|
-1.69
-25%
|
-1.94
-15%
|
-2.26
-16%
|
-2.98
-32%
|
-2.45
+18%
|
-2.06
+16%
|